Expanding the Impact of SGLT2 Inhibitors in Chronic Kidney Disease.
作者信息
Makawi Alaa T, Tawfik Yahya M K, Dixon Dave L, McMahon Gearoid M, Buckley Leo F
机构信息
Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Department of Pharmacy Practice, College of Pharmacy, Umm Al Qura University, Makkah, Saudi Arabia.
出版信息
Am J Nephrol. 2024;55(4):417-420. doi: 10.1159/000536540. Epub 2024 Feb 28.
Abstract
摘要
相似文献
1
Expanding the Impact of SGLT2 Inhibitors in Chronic Kidney Disease.扩大钠-葡萄糖协同转运蛋白2抑制剂在慢性肾脏病中的影响
Am J Nephrol. 2024;55(4):417-420. doi: 10.1159/000536540. Epub 2024 Feb 28.
2
Comment on "The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease".关于“钠-葡萄糖协同转运蛋白2抑制剂在非糖尿病慢性肾脏病患者中的疗效与安全性”的评论
Int Urol Nephrol. 2024 Jun;56(6):2115-2116. doi: 10.1007/s11255-024-03950-9. Epub 2024 Jan 22.
3
Are SGLT2 Inhibitors Ready for Prime Time for CKD?钠-葡萄糖协同转运蛋白2抑制剂对慢性肾脏病而言已准备好进入黄金时期了吗？
Clin J Am Soc Nephrol. 2018 Feb 7;13(2):318-320. doi: 10.2215/CJN.07680717. Epub 2017 Sep 11.
4
Therapeutic carbohydrate restriction and sodium-glucose transporter 2 inhibitors in chronic kidney disease: A potentially powerful combination.慢性肾脏病中的治疗性碳水化合物限制与钠-葡萄糖协同转运蛋白2抑制剂：一种潜在的强效组合。
Diabetes Obes Metab. 2023 Oct;25(10):2791-2794. doi: 10.1111/dom.15195. Epub 2023 Jun 29.
5
Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan.钠-葡萄糖共转运蛋白 2 抑制剂降低平均动脉压可改善合并慢性肾脏病的 2 型糖尿病患者的肾脏复合结局：日本倾向评分匹配模型分析。
J Diabetes Investig. 2021 Aug;12(8):1408-1416. doi: 10.1111/jdi.13491. Epub 2021 Feb 1.
6
[Patient with type 2 diabetes and progressive chronic kidney disease].[2型糖尿病合并进行性慢性肾脏病患者]
Rev Med Liege. 2025 Jan;80(1):63-68.
7
DAPA-CKD: Significant Victory for CKD with or without Diabetes.达格列净治疗慢性肾脏病（DAPA-CKD）：无论有无糖尿病的慢性肾脏病的重大胜利。
Trends Endocrinol Metab. 2021 Jun;32(6):335-337. doi: 10.1016/j.tem.2021.02.007. Epub 2021 Mar 4.
8
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.SGLT2 抑制剂对 2 型糖尿病合并慢性肾脏病患者心血管、肾脏和安全性结局的影响：系统评价和荟萃分析。
Diabetes Obes Metab. 2019 May;21(5):1237-1250. doi: 10.1111/dom.13648. Epub 2019 Mar 4.
9
SGLT-2 inhibitors: Diabetes and CKD and CHF (and gout?), oh my!钠-葡萄糖协同转运蛋白2抑制剂：糖尿病、慢性肾脏病和心力衰竭（还有痛风？），天哪！
Cleve Clin J Med. 2024 Jul 1;91(7):392-393. doi: 10.3949/ccjm.91b.07024.
10
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.SGLT2 抑制剂在 2 型糖尿病中的 CKD 和心血管疾病的作用：由美国国家肾脏基金会赞助的科学研讨会报告。
Diabetes. 2021 Jan;70(1):1-16. doi: 10.2337/dbi20-0040. Epub 2020 Oct 26.
本文引用的文献
1
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.达格列净治疗射血分数轻度降低或保留的心力衰竭。
N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27.
2
Treating Early-Stage CKD With New Medication Therapies: Results of a CKD Patient Survey Informing the 2020 NKF-FDA Scientific Workshop on Clinical Trial Considerations for Developing Treatments for Early Stages of Common, Chronic Kidney Diseases.用新药物疗法治疗早期慢性肾脏病：一项慢性肾脏病患者调查结果为2020年美国国家肾脏基金会-美国食品药品监督管理局关于常见慢性肾脏病早期治疗临床试验考量的科学研讨会提供信息
Kidney Med. 2022 Mar 7;4(4):100442. doi: 10.1016/j.xkme.2022.100442. eCollection 2022 Apr.
3
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
4
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.在肾脏病和 2 型糖尿病患者中用非奈利酮发生的心血管事件。
N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28.
5
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.达格列净在合并和不合并心力衰竭的肾脏病患者中的疗效。
JACC Heart Fail. 2021 Nov;9(11):807-820. doi: 10.1016/j.jchf.2021.06.017. Epub 2021 Aug 23.
6
Chronic kidney disease.慢性肾脏病。
Lancet. 2021 Aug 28;398(10302):786-802. doi: 10.1016/S0140-6736(21)00519-5. Epub 2021 Jun 24.
7
Generalizability of DAPA-CKD to the United States.
Circ Cardiovasc Qual Outcomes. 2021 Jul;14(7):e007875. doi: 10.1161/CIRCOUTCOMES.121.007875. Epub 2021 Jun 22.
8
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.阿司匹林在心血管疾病中的剂量比较效果。
N Engl J Med. 2021 May 27;384(21):1981-1990. doi: 10.1056/NEJMoa2102137. Epub 2021 May 15.
9
Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus.当代 2 型糖尿病患者新型心脏保护降血糖药物的资格和使用的国家模式。
J Am Heart Assoc. 2021 Jul 6;10(13):e021084. doi: 10.1161/JAHA.121.021084. Epub 2021 May 15.
10
Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: Impact of the 2020 KDIGO clinical practice guidelines.钠-葡萄糖共转运蛋白 2 抑制剂用于美国 2 型糖尿病成人的肾脏和心血管保护：2020 年 KDIGO 临床实践指南的影响。
Pharmacol Res. 2021 Apr;166:105530. doi: 10.1016/j.phrs.2021.105530. Epub 2021 Mar 3.
Zotero 插件